Therapeutic | Edrecolomab |
Target | EPCAM |
Heavy Chain | QVQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLEWIGVINPGSGGTNYNEKFKGKATLTADKSSSTAYMQLSSLTSDDSAVYFCARDGPWFAYWGQGTLVTVSA |
Light Chain | NIVMTQSPKSMSMSVGERVTLTCKASENVVTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQGYSYPYTFGGGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G2a |
Highest Clinical Trial (June '19) | Approved (w) |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 1995 |
INN Year Recommended | 1996 |
Companies Involved | Ajinomoto, Centocor Inc |
Conditions Approved | Colorectal cancer |
Conditions Active | na |
Conditions Discontinued | Adenocarcinoma, Pancreatic cancer |
Notes |